Katakami N, et al. - The goal of this work was to investigate the preventive effects of tofogliflozin, a potent and selective Sodium-glucose co-transporter-2 inhibitor, on the progression of atherosclerosis in subjects with type 2 diabetes (T2DM) using carotid intima-media thickness (IMT), an established marker of cardiovascular disease (CVD), as a marker. This is the first study to notice the impacts of Sodium-glucose co-transporter-2 inhibitors on the progression of carotid IMT in subjects with T2DM without a history of CVD. The outcomes will be available in the very near future, and these findings are expected to provide clinical data that will be helpful in the prevention of diabetic atherosclerosis and subsequent CVD.